Literature DB >> 2140256

Identification, purification, and localization of tissue kallikrein in rat heart.

W Xiong1, L M Chen, C Woodley-Miller, J A Simson, J Chao.   

Abstract

A tissue kallikrein has been isolated from rat heart extracts by DEAE-Sepharose and aprotinin-affinity column chromatography. The purified cardiac enzyme has both N-tosyl-L-arginine methyl ester esterolytic and kinin-releasing activities, and displays parallelism with standard curves in a kallikrein radioimmunoassay, indicating it to have immunological identity with tissue kallikrein. The enzyme is inhibited by aprotinin, antipain, leupeptin and by high concentrations of soybean trypsin inhibitor, but stimulated by lima-bean or ovomucoid trypsin inhibitor and low concentrations of soybean trypsin inhibitor. By using a specific monoclonal antibody to tissue kallikrein in Western blot as well as active-site labelling with [14C]di-isopropyl fluorophosphate, the cardiac enzyme was identified as a protein of 38 kDa, a molecular mass identical with that of tissue kallikrein. Immunocytochemistry at the electron-microscopic level localized this enzyme to the sarcoplasmic reticulum and granules of rat atrial myocytes. Two cardiac kallikrein precursors, (38 and 40 kDa) were identified from the translation in vitro of heart mRNA by immunoprecipitation and electrophoresis of [35S]methionine-labelled cell-free translation products. Kallikrein mRNA in the rat heart was also demonstrated by dot-blot analysis using a tissue kallikrein cDNA probe. These results indicate that the tissue kallikrein gene is expressed in the rat heart and that the purified enzyme is indistinguishable from tissue kallikrein with respect to enzymic and immunological characteristics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140256      PMCID: PMC1131345          DOI: 10.1042/bj2670639

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  39 in total

Review 1.  Kallikreins (kininogenases)--a group of serine proteases with bioregulatory actions.

Authors:  M Schachter
Journal:  Pharmacol Rev       Date:  1979-03       Impact factor: 25.468

2.  Isozymes of rat urinary kallikrein.

Authors:  J Chao; H S Margolius
Journal:  Biochem Pharmacol       Date:  1979-07-01       Impact factor: 5.858

3.  Hybridization of denatured RNA transferred or dotted nitrocellulose paper.

Authors:  P S Thomas
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

4.  "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.

Authors:  W N Burnette
Journal:  Anal Biochem       Date:  1981-04       Impact factor: 3.365

5.  Identification of tissue kallikrein in brain and in the cell-free translation product encoded by brain mRNA.

Authors:  J Chao; C Woodley; L Chao; H S Margolius
Journal:  J Biol Chem       Date:  1983-12-25       Impact factor: 5.157

6.  The radioimmunoassay of human urinary kallikrein and comparisons with kallikrein activity measurements.

Authors:  K Shimamoto; J Chao; H S Margolius
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

7.  Purification and characterization of rat urinary esterase A, a plasminogen activator.

Authors:  J Chao
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

8.  Differential effects of testosterone, thyroxine, and cortisol on rat submandibular gland versus renal kallikrein.

Authors:  J Chao; H S Margolius
Journal:  Endocrinology       Date:  1983-12       Impact factor: 4.736

9.  A direct radioimmunoassay of rat urinary kallikrein and comparison with other measures of urinary kallikrein activity.

Authors:  K Shimamoto; H S Margolius; J Chao; A R Crosswell
Journal:  J Lab Clin Med       Date:  1979-07

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  9 in total

Review 1.  Apoptosis in myocardial ischaemia and infarction.

Authors:  P A J Krijnen; R Nijmeijer; C J L M Meijer; C A Visser; C E Hack; H W M Niessen
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

2.  Tissue-specific expression and promoter analyses of the human tissue kallikrein gene in transgenic mice.

Authors:  W Xiong; J Wang; L Chao; J Chao
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

3.  Purification and characterization of recombinant tissue kallikrein from Escherichia coli and yeast.

Authors:  J Wang; J Chao; L Chao
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

4.  A kallidin-like peptide is a protective cardiac kinin, released by ischaemic preconditioning of rat heart.

Authors:  Xiuxin Liu; Martina Lukasova; Radka Zubakova; Sabina Lewicka; Ulrich Hilgenfeldt
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 5.  Kallikrein-kinin in stem cell therapy.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

6.  Kallidin-like peptide mediates the cardioprotective effect of the ACE inhibitor captopril against ischaemic reperfusion injury of rat heart.

Authors:  Xiuxin Liu; Martina Lukasova; Radka Zubakova; Sabina Lewicka; Ulrich Hilgenfeldt
Journal:  Br J Pharmacol       Date:  2006-06-12       Impact factor: 8.739

7.  Increased tissue kallikrein levels in type 2 diabetes.

Authors:  D J Campbell; A Kladis; Y Zhang; A J Jenkins; D L Prior; M Yii; J F Kenny; M J Black; D J Kelly
Journal:  Diabetologia       Date:  2010-01-10       Impact factor: 10.122

Review 8.  Development biology of the renal kallikrein-kinin system.

Authors:  S S el-Dahr
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

Review 9.  Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review).

Authors:  Marina Devetzi; Maria Goulielmaki; Nicolas Khoury; Demetrios A Spandidos; Georgia Sotiropoulou; Ioannis Christodoulou; Vassilis Zoumpourlis
Journal:  Int J Mol Med       Date:  2018-01-03       Impact factor: 4.101

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.